What is Spero Therapeutics, Inc.'s earnings per share (EPS)?

Spero Therapeutics, Inc. (SPRO) reported diluted earnings per share of $0.15 for fiscal year 2025. This represents a 111.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Spero Therapeutics, Inc. (SPRO) Financials

SPRO

Trailing 12 months to June 30, 2026

Revenue $47.0M -3.3% YoY

Net Income $7.4M +113.8% YoY

EPS (Diluted) $0.14 +114.3% YoY

Operating Cash Flow $19.6M +160.6% YoY

Market Cap $69.3M as of Oct 3, 2026

Price / Sales 1.5x on $47.0M revenue, trailing 12 months to June 30, 2026

Price / Earnings 9.4x on $7.4M net income, trailing 12 months to June 30, 2026

Price / Book 1.6x on $44.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SPRO SEC filings page.

Spero Therapeutics, Inc. (SPRO) reported $47.0M in revenue over the twelve months to Jun 30, 2026, down 3.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SPRO FY2025 2026-10-03

Spero’s reported profitability is episodic: FY2025 returned to profit, but operating cash flow remained negative and development spending shaped margins.

The profit-to-cash gap persisted in FY2025: net income was $8.6M while operating cash flow was -$12.6M. FY2023 showed the same pattern, with net income of $22.8M alongside operating cash flow of -$33.0M, so reported earnings have not consistently represented cash generation.

Operating margin swung from -152.9% in FY2024 to 9.5%, making reported profit highly sensitive to annual spending levels. That inflection coincided with R&D falling from $96.8M to $38.5M, indicating spending intensity—not just revenue scale—did much of the work.

FY2025’s debt-to-equity was 0.2x and its current ratio was 7.6x, indicating a lighter liability burden and greater short-term asset coverage than FY2024. The supplied liquidity measure equals 38.3 months of the latest annual reported operating outflow, but the negative cash flow shows liquidity and cash generation remain separate questions.

Financial Health Signals

Financial Health Score 65/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Spero Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Spero Therapeutics, Inc. held $40.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $12.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Spero Therapeutics, Inc. scores 62/100 among other emerging companies.

Dilution

Spero Therapeutics, Inc. had 58M shares outstanding at the end of fiscal year 2025, against 56M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Spero Therapeutics, Inc. scores 60/100 among other emerging companies.

R&D Intensity

Spero Therapeutics, Inc. spent $38.5M on research and development in fiscal year 2025, which was 63.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Spero Therapeutics, Inc. scores 86/100 among other emerging companies.

Revenue Progress

Spero Therapeutics, Inc. reported revenue of $66.8M in fiscal year 2025, against $48.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Spero Therapeutics, Inc. scores 20/100 among other emerging companies.

Burn Trend

Spero Therapeutics, Inc.'s operations used $12.6M of cash in fiscal year 2025, against $23.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Spero Therapeutics, Inc. scores 75/100 among other emerging companies.

Balance Sheet

Spero Therapeutics, Inc.'s cash, cash equivalents and investments came to $40.3M at the end of fiscal year 2025, against $9.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Spero Therapeutics, Inc. scores 86/100 among other emerging companies.

Altman Z-Score Distress

-2.67

Spero Therapeutics, Inc. scores -2.67, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($69.3M) relative to total liabilities ($9.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/7

Spero Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

$1.47used

For every $1 of reported earnings, Spero Therapeutics, Inc. used $1.47 of operating cash (-$12.6M OCF vs $8.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

QoQ-100.0%

Spero Therapeutics, Inc. generated $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Net Income

-$9.6M

YoY-461.9%

QoQ-32.6%

Spero Therapeutics, Inc. reported -$9.6M in net income in Q2 2026. This represents a decrease of 461.9% from the same quarter a year earlier. Against the prior quarter it is down 32.6%.

EPS (Diluted)

-$0.16

YoY-433.3%

QoQ-23.1%

Spero Therapeutics, Inc. earned -$0.16 per diluted share (EPS) in Q2 2026. This represents a decrease of 433.3% from the same quarter a year earlier. Against the prior quarter it is down 23.1%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$50.8M

YoY+62.8%

QoQ-9.5%

5Y CAGR-6.6%

Spero Therapeutics, Inc. held $50.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

58M

YoY+3.5%

QoQ+0.6%

5Y CAGR+12.6%

Spero Therapeutics, Inc. had 58M shares outstanding in Q2 2026. This represents an increase of 3.5% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-21.6%

YoY-16.4pp

QoQ-8.0pp

5Y change-1.0pp

Spero Therapeutics, Inc.'s ROE was -21.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 16.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$3.4M

YoY-67.8%

QoQ+18.0%

5Y CAGR-25.0%

Spero Therapeutics, Inc. invested $3.4M in research and development in Q2 2026. This represents a decrease of 67.8% from the same quarter a year earlier. Against the prior quarter it is up 18.0%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

SPRO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SPRO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	$47.0M	$66.8M+39.2%	$48.0M-53.8%	$103.8M+94.0%	$53.5M+193.1%	$18.3M+95.7%	$9.3M-48.6%	$18.1M+357.6%	$4.0M+100.4%	$2.0M+490.7%	$335K	N/A
R&D Expenses	$20.5M	$38.5M-60.2%	$96.8M+88.1%	$51.4M+8.1%	$47.6M-26.2%	$64.5M-3.7%	$67.0M+1.9%	$65.8M+94.1%	$33.9M+3.1%	$32.9M+24.8%	$26.3M+136.7%	$11.1M
SG&A Expenses	$19.9M	$21.2M-10.7%	$23.7M-7.2%	$25.6M-30.0%	$36.5M-12.5%	$41.7M+94.5%	$21.4M+37.5%	$15.6M+21.0%	$12.9M+18.9%	$10.8M+50.1%	$7.2M+228.0%	$2.2M
Operating Income	$6.0M	$6.3M+108.6%	-$73.4M-441.5%	$21.5M+150.9%	-$42.2M+52.0%	-$88.0M-11.2%	-$79.1M-25.1%	-$63.2M-47.7%	-$42.8M-2.6%	-$41.7M-25.6%	-$33.2M-149.3%	-$13.3M
EBITDA	N/A	$6.3M+108.6%	-$73.4M-435.8%	$21.8M+152.9%	-$41.3M+52.7%	-$87.3M-11.5%	-$78.4M-25.4%	-$62.5M-47.3%	-$42.4M-2.5%	-$41.4M-25.6%	-$32.9M-147.4%	-$13.3M
Income Tax	N/A	$261K	$0-100.0%	$2.6M	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	$7.4M	$8.6M+112.5%	-$68.6M-400.6%	$22.8M+149.1%	-$46.4M+48.3%	-$89.8M-14.7%	-$78.3M-28.6%	-$60.9M-46.0%	-$41.7M-7.6%	-$38.7M-52.0%	-$25.5M-149.9%	-$10.2M
EPS (Basic)	N/A	$0.15+111.8%	-$1.27-395.3%	$0.43+135.0%	-$1.23+57.7%	-$2.91	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.14	$0.15+111.8%	-$1.27-395.3%	$0.43+135.0%	-$1.23+57.7%	-$2.91	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	59M+9.3%	54M+2.0%	53M+41.0%	38M+21.7%	31M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0-100.0%	$258K-95.6%	$41.3M+174.5%	$5.4M-59.6%	$14.2M+39.1%	$5.9M-36.6%	$15.0M-79.5%	$13.5M-47.1%
R&D Expenses	$3.4M-67.8%	$2.9M-78.6%	$5.6M-80.6%	$8.6M-68.0%	$10.7M-55.0%	$13.6M-21.5%	$28.8M+74.2%	$26.9M+63.9%
SG&A Expenses	$6.5M+10.4%	$4.9M-28.4%	$4.3M-39.1%	$4.2M-19.7%	$5.9M+6.2%	$6.8M+15.3%	$7.1M+9.7%	$5.2M-8.9%
Operating Income	-$9.9M-306.1%	-$7.5M+48.8%	$31.4M+244.6%	-$7.9M+57.4%	-$2.4M+87.2%	-$14.7M-5.4%	-$21.7M-143.0%	-$18.6M-861.4%
EBITDA	N/A	N/A	N/A	-$7.9M+57.4%	N/A	N/A	-$21.7M-143.0%	-$18.6M-918.2%
Income Tax	N/A	N/A	N/A	$0-100.0%	N/A	N/A	N/A	$290K-86.9%
Net Income	-$9.6M-461.9%	-$7.2M+48.1%	$31.5M+250.9%	-$7.4M+56.9%	-$1.7M+90.5%	-$13.9M-9.4%	-$20.9M-140.8%	-$17.1M-435.8%
EPS (Basic)	-$0.16-433.3%	-$0.13+48.0%	$0.56+247.4%	-$0.13+59.4%	-$0.03+90.9%	-$0.25-4.2%	-$0.38-139.2%	-$0.32-433.3%
EPS (Diluted)	-$0.16-433.3%	-$0.13+48.0%	$0.56+247.4%	-$0.13+59.4%	-$0.03+90.9%	-$0.25-4.2%	-$0.38-139.2%	-$0.32-433.3%
Diluted Shares (Avg)	58M+3.5%	57M+3.4%	N/A	56M+4.0%	56M+3.8%	55M+3.5%	N/A	54M+2.7%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

SPRO Balance Sheet

SPRO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$68.9M-37.7%	$110.5M-39.4%	$182.4M+46.1%	$124.8M-27.0%	$171.1M+11.5%	$153.5M+44.6%	$106.1M-17.8%	$129.0M+38.0%	$93.5M+578.8%	$13.8M	N/A
Current Assets	$67.3M-37.3%	$107.3M-18.2%	$131.2M+15.5%	$113.6M-28.1%	$157.9M+13.5%	$139.1M+45.8%	$95.4M-23.2%	$124.2M+34.9%	$92.1M+675.4%	$11.9M	N/A
Cash & Equivalents	$40.3M-23.9%	$52.9M-30.7%	$76.3M-30.0%	$109.1M-3.1%	$112.6M+32.1%	$85.2M+186.6%	$29.7M-12.8%	$34.1M-61.0%	$87.3M+746.2%	$10.3M+81.3%	$5.7M
Short-Term Investments	$0	$0	$0	$0-100.0%	$33.8M-18.9%	$41.7M-20.3%	$52.3M-35.7%	$81.4M	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$9.9M-84.6%	$64.4M-14.7%	$75.5M+54.5%	$48.9M-41.0%	$82.8M+286.6%	$21.4M-32.1%	$31.5M+139.7%	$13.2M+54.3%	$8.5M-85.6%	$59.2M	N/A
Current Liabilities	$8.9M-81.9%	$49.1M+32.1%	$37.2M+71.6%	$21.6M+16.0%	$18.7M+30.2%	$14.3M-46.2%	$26.7M+116.5%	$12.3M+51.0%	$8.2M+17.9%	$6.9M	N/A
Non-Current Liabilities	$1.0M-93.3%	$15.3M-60.0%	$38.3M+40.9%	$27.2M-57.5%	$64.1M+807.1%	$7.1M+45.3%	$4.9M+484.2%	$833K+128.2%	$365K-99.3%	$52.3M	N/A
Total Equity	$59.0M+28.0%	$46.1M-56.9%	$106.9M+40.8%	$75.9M-14.0%	$88.3M-33.1%	$132.0M+77.1%	$74.6M-35.4%	$115.5M+36.5%	$84.6M+286.2%	-$45.4M-144.9%	-$18.6M
Retained Earnings	-$451.1M+1.9%	-$459.6M-17.5%	-$391.1M+5.5%	-$413.9M-12.6%	-$367.5M-32.3%	-$277.7M-39.3%	-$199.4M-44.0%	-$138.5M-43.0%	-$96.8M-113.1%	-$45.4M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$52.8M-15.1%	$59.0M-24.0%	$68.9M-37.7%	$54.2M-59.9%	$62.1M-58.6%	$77.7M-53.7%	$110.5M-39.4%	$135.2M+26.2%
Current Assets	$51.6M-13.2%	$57.6M-22.9%	$67.3M-37.3%	$52.3M-60.2%	$59.4M-51.4%	$74.7M-46.7%	$107.3M-18.2%	$131.6M+28.8%
Cash & Equivalents	$50.8M+62.8%	$56.1M+14.8%	$40.3M-23.9%	$48.6M-36.3%	$31.2M-50.9%	$48.9M-40.6%	$52.9M-30.7%	$76.3M-18.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$8.6M-70.8%	$6.1M-86.1%	$9.9M-84.6%	$27.7M-60.3%	$29.3M-57.8%	$43.9M-38.6%	$64.4M-14.7%	$69.7M+30.4%
Current Liabilities	$8.4M-43.6%	$5.5M-81.2%	$8.9M-81.9%	$13.6M-72.2%	$14.9M-67.2%	$29.2M-30.3%	$49.1M+32.1%	$49.1M+92.8%
Non-Current Liabilities	$134K-99.1%	$598K-95.9%	$1.0M-93.3%	$14.0M-31.8%	$14.3M-39.6%	$14.7M-50.3%	$15.3M-60.0%	$20.6M-26.4%
Total Equity	$44.2M+34.7%	$52.9M+56.5%	$59.0M+28.0%	$26.5M-59.6%	$32.8M-59.2%	$33.8M-64.9%	$46.1M-56.9%	$65.5M+22.0%
Retained Earnings	-$467.8M+1.6%	-$458.3M+3.2%	-$451.1M+1.9%	-$482.6M-10.0%	-$475.2M-12.7%	-$473.5M-17.3%	-$459.6M-17.5%	-$438.8M+0.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

SPRO Cash Flow Statement

SPRO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	$19.6M	-$12.6M+46.2%	-$23.4M+28.9%	-$33.0M-326.8%	-$7.7M+88.0%	-$64.3M+25.1%	-$85.9M-71.7%	-$50.0M-26.2%	-$39.6M-1.3%	-$39.1M-35.1%	-$29.0M-201.4%	-$9.6M
Depreciation & Amortization	N/A	$0-100.0%	$2K-99.5%	$367K-57.8%	$869K+34.5%	$646K-15.1%	$761K+1.5%	$750K+83.4%	$409K+12.7%	$363K+30.1%	$279K+2436.4%	$11K
Stock-Based Compensation	N/A	$4.3M-44.5%	$7.8M-1.8%	$7.9M-13.1%	$9.1M-3.3%	$9.4M+92.9%	$4.9M+29.4%	$3.8M+37.4%	$2.7M+92.6%	$1.4M+692.8%	$180K+757.1%	$21K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$157K-50.0%	$314K-87.1%	$2.4M+8922.2%	$27K-96.7%	$830K+257.8%	$232K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$86.0M-70.9%	-$50.3M-19.7%	-$42.1M-7.5%	-$39.1M-31.4%	-$29.8M-202.7%	-$9.8M
Investing Cash Flow	N/A	N/A	N/A	$0-100.0%	$33.8M+340.7%	$7.7M-26.7%	$10.5M-64.5%	$29.5M+135.5%	-$83.2M-307885.2%	-$27K+96.7%	-$830K	N/A
Financing Cash Flow	N/A	N/A	$0-100.0%	$221K+100.7%	-$29.6M-135.2%	$84.0M-35.8%	$130.9M+710.9%	$16.1M-76.8%	$69.5M-40.1%	$116.1M+237.4%	$34.4M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$5.4M+69.7%	$15.9M+496.4%	-$8.4M+64.3%	$17.4M+36.5%	-$17.7M+5.6%	-$4.0M-167.4%	-$23.4M-33.8%	$12.8M-19.8%
Depreciation & Amortization	N/A	N/A	$0	$0	N/A	N/A	$0-100.0%	$0-100.0%
Stock-Based Compensation	$822K+15.1%	$1.1M-28.4%	N/A	$1.0M-51.3%	$714K-66.2%	$1.6M-23.1%	N/A	$2.2M+12.9%
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

SPRO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SPRO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Margin	9.4%	-152.9%	20.7%+99.6pp	-78.9%	-481.9%	-847.9%	-348.4%	-1079.3%	-2108.6%	-9916.7%	N/A
Net Margin	12.8%	-142.9%	22.0%+108.7pp	-86.7%	-491.9%	-839.2%	-335.6%	-1051.4%	-1957.7%	-7609.3%	N/A
Return on Equity	14.5%+163.2pp	-148.7%-170.0pp	21.3%+82.5pp	-61.1%+40.6pp	-101.7%-42.4pp	-59.3%+22.4pp	-81.7%-45.6pp	-36.1%+9.7pp	-45.8%	N/A	N/A
Return on Assets	12.4%+74.5pp	-62.0%-74.5pp	12.5%+49.7pp	-37.2%+15.3pp	-52.5%-1.5pp	-51.0%+6.4pp	-57.4%-25.1pp	-32.3%+9.1pp	-41.4%+143.6pp	-185.1%	N/A
Current Ratio	7.59+5.4x	2.19-1.3x	3.53-1.7x	5.25-3.2x	8.46-1.2x	9.70+6.1x	3.58-6.5x	10.08-1.2x	11.29+9.6x	1.72	N/A
Debt-to-Equity	0.17-1.2x	1.40+0.7x	0.71+0.1x	0.64-0.3x	0.94+0.8x	0.16-0.3x	0.42+0.3x	0.110.0x	0.10	N/A	N/A
Asset Turnover	0.97+0.5x	0.43-0.1x	0.57+0.1x	0.43+0.3x	0.110.0x	0.06-0.1x	0.17+0.1x	0.030.0x	0.020.0x	0.02	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	-922.1%	-277.4%	-1060.5%	-1977.7%	-8892.2%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	-2921.7%	76.0%	-145.5%	-17.2%	-250.8%	-144.4%	-138.0%
Net Margin	N/A	-2791.9%	76.3%	-135.7%	-12.0%	-236.1%	-138.8%	-127.3%
Return on Equity	-21.6%-16.4pp	-13.6%+27.4pp	53.4%+98.7pp	-27.9%-1.7pp	-5.2%+17.0pp	-41.0%-27.9pp	-45.3%-93.2pp	-26.2%-20.2pp
Return on Assets	-18.1%-15.4pp	-12.2%+5.6pp	45.7%+64.6pp	-13.6%-0.9pp	-2.7%+9.2pp	-17.8%-10.3pp	-18.9%-47.0pp	-12.7%-9.7pp
Current Ratio	6.12+2.1x	10.50+7.9x	7.59+5.4x	3.83+1.2x	3.97+1.3x	2.56-0.8x	2.19-1.3x	2.68-1.3x
Debt-to-Equity	0.19-0.7x	0.12-1.2x	0.17-1.2x	1.040.0x	0.890.0x	1.30+0.6x	1.40+0.7x	1.06+0.1x
Asset Turnover	0.00-0.2x	0.00-0.1x	0.60+0.5x	0.100.0x	0.23+0.2x	0.080.0x	0.14-0.3x	0.10-0.1x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Spero Therapeutics, Inc. SPRO	FY2025	$66.8M	$8.6M	12.8%	$69.3M	65/100
Zentalis Pharmaceuticals, Inc. ZNTL	FY2025	$0	-$137.1M	N/A	$238.6M	—
Armata Pharmaceuticals, Inc. ARMP	FY2025	N/A	-$173.8M	N/A	$130.9M	—
Atossa Therapeutics, Inc. ATOS	FY2025	N/A	-$34.8M	N/A	$23.4M	—
HilleVax, Inc. HLVX	FY2024	N/A	-$147.3M	N/A	$104.8M	—
MacroGenics, Inc. MGNX	FY2025	$149.5M	-$75K	-0.1%	$228.0M	57/100

Where Spero Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Spero Therapeutics, Inc.'s annual revenue?

Spero Therapeutics, Inc. (SPRO) reported $66.8M in total revenue for fiscal year 2025. This represents a 39.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Spero Therapeutics, Inc.'s revenue growing?

Spero Therapeutics, Inc. (SPRO) revenue grew by 39.2% year-over-year, from $48.0M to $66.8M in fiscal year 2025.

Is Spero Therapeutics, Inc. profitable?

Yes, Spero Therapeutics, Inc. (SPRO) reported a net income of $8.6M in fiscal year 2025, with a net profit margin of 12.8%.

What is Spero Therapeutics, Inc.'s EBITDA?

Spero Therapeutics, Inc. (SPRO) had EBITDA of $6.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Spero Therapeutics, Inc.'s operating margin?

Spero Therapeutics, Inc. (SPRO) had an operating margin of 9.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Spero Therapeutics, Inc.'s net profit margin?

Spero Therapeutics, Inc. (SPRO) had a net profit margin of 12.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Spero Therapeutics, Inc.'s return on equity (ROE)?

Spero Therapeutics, Inc. (SPRO) has a return on equity of 14.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Spero Therapeutics, Inc.'s operating cash flow?

Spero Therapeutics, Inc. (SPRO) recorded an outflow of $12.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Spero Therapeutics, Inc.'s total assets?

Spero Therapeutics, Inc. (SPRO) had $68.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Spero Therapeutics, Inc. spend on research and development?

Spero Therapeutics, Inc. (SPRO) invested $38.5M in research and development during fiscal year 2025.

How many shares does Spero Therapeutics, Inc. have outstanding?

Spero Therapeutics, Inc. (SPRO) had 58M shares outstanding as of fiscal year 2025.

What is Spero Therapeutics, Inc.'s current ratio?

Spero Therapeutics, Inc. (SPRO) had a current ratio of 7.59 as of fiscal year 2025, which is generally considered healthy.

What is Spero Therapeutics, Inc.'s debt-to-equity ratio?

Spero Therapeutics, Inc. (SPRO) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Spero Therapeutics, Inc.'s return on assets (ROA)?

Spero Therapeutics, Inc. (SPRO) had a return on assets of 12.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Spero Therapeutics, Inc.'s P/E ratio?

Spero Therapeutics, Inc. (SPRO) trades at 9.4x earnings, its market capitalization divided by net income of $7.4M net income, trailing 12 months to June 30, 2026. The market capitalization is $69.3M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Spero Therapeutics, Inc.'s price-to-sales ratio?

Spero Therapeutics, Inc. (SPRO) trades at 1.5x sales, its market capitalization divided by revenue of $47.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $69.3M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Spero Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Spero Therapeutics, Inc. (SPRO) held $40.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.6M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Spero Therapeutics, Inc.'s Altman Z-Score?

Spero Therapeutics, Inc. (SPRO) has an Altman Z-Score of -2.67, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Spero Therapeutics, Inc.'s Piotroski F-Score?

Spero Therapeutics, Inc. (SPRO) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Spero Therapeutics, Inc.'s earnings high quality?

For every $1 of reported earnings, Spero Therapeutics, Inc. (SPRO) used $1.47 of operating cash (-$12.6M OCF vs $8.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Spero Therapeutics, Inc.?

Spero Therapeutics, Inc. (SPRO) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.